Abstract

Herein we tested a nanosized cancer-cell targeted delivery system based on cytochrome c (Cyt c) and hyaluronic acid. Cyt c was chosen since it is a per se non-toxic protein but causes apoptosis when delivered to the cytoplasm of target cells. Hyaluronic acid was employed to create the nanosized delivery system with passive targeting capability in order to exploit the enhanced permeation and retention (EPR) effect and active targeting capability of hyaluronic acid. In addition, our goal was to incorporate a smart release strategy to only promote protein release upon reaching its target.Nanoparticles were formed by a simple yet precise nanoprecipitation process based on desolvation. They were physically characterized to select precipitation conditions leading to adequate size, shape, protein bioactivity, and protein loading to produce a feasible targeted cancer treatment. We synthesized nanoparticles of around 500 nm diameter with a 60% protein loading and more than 80% of protein bioactivity. In vitro, cumulative release of 92% of Cyt c was observed after 8 h under conditions mimicking the reductive intracellular environment, while under non-denaturing conditions only 20% was released. The nanoparticles displayed a selective cytotoxic effect on cancer cells. After 6 h of incubation with the nanoparticles, hyaluronic acid receptor over expressing A549 human lung adenocarcinoma cells showed a viability of ca. 20% at 0.16 mg/ml of Cyt c concentration. Only a negligible effect was observed on viability of COS-7 African green monkey kidney fibroblast, a normal cell line notoverexpressing the hyaluronic acid receptor. Confocal microscopy confirmed that the drug delivery system indeed delivered Cyt c to the cytoplasm of the target cells. We conclude that we were able to create a smart stimuli-responsive targeted drug delivery system with significant potential in cancer therapy.

Highlights

  • Cancer is a descriptive term for a cluster of heterogeneous diseases with some similarities according to the National Cancer Institute

  • Tumors must generate blood vessels quite early to allow for sufficient nutrients to reach the core but the rapid growth of new vasculature produces leaky blood vessels and poor lymphatic drainage, which can be advantageously exploited in drug delivery systems (DDS) [2]

  • We developed a cytochrome c (Cyt c)-Hyaluronic acid (HA) based DDS which showed systemic selectivity towards CD44positive cancer cells when compared to clusterdifferentiation 44 (CD44)-negative normal cells [27]

Read more

Summary

Introduction

There are common hallmarks of cancers that can be exploited to develop delivery and treatment strategies. It is known that passive accumulation of nanoparticles (NPs) at solid tumors can be achieved by exploiting the Enhanced Permeation and Retention (EPR) effect, first described by Maeda and colleagues [1]. It has been found that DDS must accumulate through passive targeting in the tumor site first in order to take advantage of active targeting strategies if incorporated in the system [5]. NP formation and stimuli responsive characteristics can be incorporated into DDS to improve targetability, minimizing undesired side effects, which are one the main flaws of conventional cancer chemotherapy

Objectives
Methods
Results
Conclusion
Full Text
Published version (Free)

Talk to us

Join us for a 30 min session where you can share your feedback and ask us any queries you have

Schedule a call